Latest News and Press Releases
Want to stay updated on the latest news?
-
Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancersFirst-in-class multi-checkpoint inhibitor with robust efficacy and safetyCombination arm with pembrolizumab...